Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-16T16:32:23.814Z Has data issue: false hasContentIssue false

Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections

Published online by Cambridge University Press:  13 May 2025

Lauren C. Russell
Affiliation:
Deparment of Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, USA
Jeff Klaus
Affiliation:
Deparment of Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, USA
Miguel A. Chavez
Affiliation:
Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine in St. Louis, Saint Louis, MO, USA
Erik R. Dubberke*
Affiliation:
Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine in St. Louis, Saint Louis, MO, USA
Tamara Krekel
Affiliation:
Deparment of Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, USA
*
Corresponding author: Erik R. Dubberke; Email: edubberk@wustl.edu

Abstract

The safety of the utilization of methicillin-susceptible Staphylococcus aureus (MSSA)-targeted therapy for the treatment of MSSA bloodstream infections in the setting of neutropenia is not well studied. This single-center, retrospective cohort study of 40 patients found no significant difference in clinical outcomes between broad-spectrum anti-Pseudomonal and MSSA-targeted beta-lactam therapy.

Information

Type
Concise Communication
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Baseline patient/treatment characteristics

Figure 1

Table 2.Primary and secondary outcomes

Supplementary material: File

Russell et al. supplementary material

Russell et al. supplementary material
Download Russell et al. supplementary material(File)
File 359.4 KB